Genomics CEO Says Vertex R&D Pact, £25m Series B Secure Its Viability
Executive Summary
The Oxford biotech raised £25m from investors and inked a collaboration with Vertex that's probably worth tens of millions of pounds, maybe much more. The founder and CEO of Genomics PLC tells Scrip the four-year-old company will also seek other pharma alliances.